Switching to the new fPELA turbo assay for improved workflow and efficiency Kaleem Fayyaz, Blood Sciences Team Leader, Spire Manchester Hospital Spire Healthcare is a leading UK independent hospital group. It delivers high standards of care to insured, self-pay and NHS patients across 39 hospitals and 8 clinics. The laboratories at Spire Manchester Hospital provide…
From the Siemens Advia 2400 to the Atellica Analyser Georgette Glover, Senior Biomedical Scientist, Biochemistry Department, Addenbrookes Hospital Addenbrookes Hospital has been using the BÜHLMANN calprotectin assays for a number of years. They initially employed the fCAL® ELISA with the CALEX® sample extraction device, processed on a Dynex DS2 automated system. However, in December 2018…
An interview with Yvonne Schallberger, Bioanalytica, Lucerne, Switzerland Mrs. Schallberger decided to introduce the BÜHLMANN fPELA® turbo Test, that measures in random access as well as in batch mode the faecal pancreatic elastase in a minimum time of 10 minutes. This can be done on most clinical chemistry analysers on the market. Mrs. Schallenberger, what…
Testimonial from Angela Suter and Dr. Cyril Fuhrer, Synlab Suisse SA, Lucerne, Switzerland You are successfully performing routine faecal calprotectin measurements with the BÜHLMANN fCAL® turbo Assay on the Beckman Coulter AU 5800. What are your experiences with applying a CALEX® Cap faecal extract onto a high throughput analyser in your routine? The test is…
A report from Dr. Marc-Antoine Bagnoud*, Dianalabs in Geneva, Switzerland Dianalabs is a mid-sized private lab founded in 1988 in Geneva, Switzerland, and part of the large swiss lab network Medisupport group with a total of 900 employees. Dr. Marc- Antoine Bagnoud, laboratory director of clinical chemistry at Dianalabs talked with us about the successful…
Jacqui McGuire and Neil Syme, Consultant Clinical Biochemists, Department of Biochemistry, Monklands Hospital NHS Lanarkshire, to the east of Glasgow, is the third largest NHS Health Board in Scotland. It serves 655,000 people at the Hairmyres, Wishaw and Monklands Hospitals. Faecal calprotectin testing for the diagnosis and monitoring of inflammatory bowel diseases is conducted at…
BÜHLMANN has been the market leading provider of faecal calprotectin assays in the UK for over 10 years, holding a significant portion of the market share, as recorded on the National External Quality Assurance Scheme (NEQAS). The BÜHLMANN results are split across the two main laboratory assays: fCAL ELISA and fCAL turbo assays. There is…
COVID has caused many changes in our day to day lives, with freedom and services intermittently restricted as the infection rates surge and abate. This pattern has also been evident in our healthcare system as we have previously reported to you. A UK on-line survey in 2020 of 125 hospitals (Kennedy et al. Frontline Gastroenterology)…